Cerenis Therapeutics--which has operations in Ann Arbor, MI and Toulouse, France focused on developing a new cholesterol drug--has raised $53.5 million in its second round of venture financing. TVM Capital led the round with additional funds from Orbimed, Sofinnova Partners of France, HealthCap of Sweden, Alta Partners and EDF Ventures of the U.S. and NIF SMBC Ventures of Japan. Cerenis says much of the money will be used to back the development of its lead compound, Cerenis HDL, a synthetic form of HDL (high-density lipoprotein, also known as "good cholesterol") that mimics natural HDL in humans.
- here's the release on the latest round
ALSO: Yaupon Therapeutics has raised $4 million in its second round of financing. Release